Literature DB >> 18834340

Low-dose sublingual misoprostol versus methylergometrine for active management of the third stage of labor.

Shakuntala Chhabra1, Chandan Tickoo.   

Abstract

OBJECTIVE: To compare the efficacy and side-effects of low-dose sublingual misoprostol and i.v. methylergometrine for active management of the third stage of labor.
METHODS: The study subjects were three hundred low-risk women with term pregnancy and spontaneous onset of labor. These women received either one (100 microg/tablet) or two tablets of misoprostol (200 microg) sublingually or 1 mL (200 microg) of methylergometrine, i.v. injection, after the delivery of the anterior shoulder of the baby. The main outcome measures were the need for additional oxytocic drugs, blood loss >or=500 mL, change in hemoglobin levels and side-effects.
RESULTS: Post-partum hemorrhage (>or=500 mL blood loss) did not occur in any of the women, but above-average bleeding occurred in 2.0% of cases in groups I, II (sublingual misoprostol 100 microg and 200 microg respectively) and III (methylergometrine), despite additional oxytocics used in 5.0%, 4.0% and 3.0% cases in groups I, II and III respectively (P>0.05). The change in hemoglobin levels at 24 h post-partum were 0.8%, 0.7% and 0.8% in groups I, II and III respectively (P>0.05).
CONCLUSION: A low dose of sublingual misoprostol appears to be as effective as a low dose of i.v. methylergometrine in the prevention of post-partum hemorrhage in low-risk cases. So given the advantages of its stability at room temperature, low cost and easy route of administration, misoprostol appears to be a better choice, and a low dose is enough. However, larger studies in low-risk as well as high-risk cases are needed to advocate routine use of a low dose at the primary level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18834340     DOI: 10.1111/j.1447-0756.2008.00843.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  7 in total

Review 1.  Postpartum haemorrhage: prevention.

Authors:  David Chelmow
Journal:  BMJ Clin Evid       Date:  2011-04-04

Review 2.  Prostaglandins for preventing postpartum haemorrhage.

Authors:  Özge Tunçalp; G Justus Hofmeyr; A Metin Gülmezoglu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

3.  Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.

Authors:  Ioannis D Gallos; Argyro Papadopoulou; Rebecca Man; Nikolaos Athanasopoulos; Aurelio Tobias; Malcolm J Price; Myfanwy J Williams; Virginia Diaz; Julia Pasquale; Monica Chamillard; Mariana Widmer; Özge Tunçalp; G Justus Hofmeyr; Fernando Althabe; Ahmet Metin Gülmezoglu; Joshua P Vogel; Olufemi T Oladapo; Arri Coomarasamy
Journal:  Cochrane Database Syst Rev       Date:  2018-12-19

4.  Efficacy of rectal misoprostol for prevention of postpartum hemorrhage.

Authors:  Masoumeh Mirteimouri; Fatemeh Tara; Batool Teimouri; Nahid Sakhavar; Afsaneh Vaezi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

5.  Management of third stage of labor with misoprostol: A comparison of three routes of administration.

Authors:  Sukhwinder Kaur Bajwa; Sukhminder Jit Singh Bajwa; Harpreet Kaur; S P S Goraya; Anita Singh; Harpreet Kaurishar
Journal:  Perspect Clin Res       Date:  2012-07

Review 6.  Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.

Authors:  Ioannis D Gallos; Helen M Williams; Malcolm J Price; Abi Merriel; Harold Gee; David Lissauer; Vidhya Moorthy; Aurelio Tobias; Jonathan J Deeks; Mariana Widmer; Özge Tunçalp; Ahmet Metin Gülmezoglu; G Justus Hofmeyr; Arri Coomarasamy
Journal:  Cochrane Database Syst Rev       Date:  2018-04-25

7.  Misoprostol for primary versus secondary prevention of postpartum haemorrhage: a cluster-randomised non-inferiority community trial.

Authors:  S Raghavan; S Geller; S Miller; S S Goudar; H Anger; M C Yadavannavar; R Dabash; S R Bidri; M R Gudadinni; R Udgiri; A R Koch; M B Bellad; B Winikoff
Journal:  BJOG       Date:  2015-09-01       Impact factor: 6.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.